Day 1 - Tuesday, 22 May 2018
Meeting category
Date(s)
22 May 2018 - 24 May 2018
Location
Baltimore,
United States
Organizer
Titanium Level Support
Sponsor logos
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Related Enduring Materials
Enduring Materials
Day 2 - Wednesday, 23 May 2018
Session 2: Hepatitis related topic - 08:30
08:30 CEST
The use of DAA’s in pregnancy in HCV infected mothers
09:00 CEST
Clinical case presentation
09:30 CEST
Tenofovir exposure during pregnancy and postpartum in hepatitis B mono-infected women on TDF monotherapy compared to HIV-infected women on TDF-containing antiretroviral therapy
09:45 CEST
Intracellular 007-TP Concentrations are Associated with Gradients of Adherence to Ledipasvir/Sofosbuvir
10:00 CEST
A Pharmacometabolomics Approach for Predicting Tenofovir diphosphate (TFV-DP) Concentrations in Dried Blood Spots (DBS)
Session 3: Round Table discussion: validation of Physiologically based pharmacokinetic (PBPK) modeling - 11:00
11:20 CEST
Application of PBPK modelling for assessment of DDI liability in combination therapies
Karen Yeo, PhD
Simcyp Limited, UK
11:40 CEST
Physiologically based pharmacokinetic modeling and simulation in drug product development and review
Session 4: Towards Precision Medicine - 14:00
14:30 CEST
Last advances in HIV pharmacogenomics
15:00 CEST
SLC22a2 genetic variants and dolutegravir trough concentrations correlate with specific psychiatric symptoms in hiv-positive patients on dolutegravir
15:15 CEST
Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals' Concentrations
Short Poster Presentations; "Best of Posters"
Assessment of maternal and fetal dolutegravir exposure by integrating ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling
Freriksen
Reduced nevirapine concentrations among HIV-positive women receiving mefloquine for intermittent preventive treatment for malaria control during pregnancy
Haaland
Session 5: HIV related topic - 16:30
16:30 CEST
Clinical Pharmacology of Integrase Inhibitors
17:00 CEST
Clinical case presentation
17:30 CEST
Bictegravir/Emtricitabine/Tenofovir Alafenamide Phase 3 Exposure-Response Analysis of Safety and Efficacy in the Treatment of HIV Infection
Lutz
-
17:45 CEST
Pharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon
18:00 CEST
First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women
Day 3 - Thursday, 24 May 2018
Session 6: Drug - Drug interactions related session - 08:30
08:50 CEST
Update on DDI guidelines of the FDA - in vivo
09:10 CEST
Medication safety issues associated with currently used first-line antiretroviral regimens in Uganda
09:25 CEST
Intraindividual comparison of efavirenz, atazanavir, or ritonavir plasma pharmacokinetics before and during 21-days of vaginally administered hormone contraception
09:40 CEST
Pharmacokinetics of dolutegravir 100 mg once-daily with rifampicin
Wang
-
09:55 CEST
Rifabutin (RBT) Decreases Cabotegravir (CAB) Exposure following Oral Co-administration
10:10 CEST
Rifabutin PK and Safety among HIV/TB Coinfected Children Receiving Lopinavir
10:55 CEST
Clinical Pharmacology of HIV Pre-Exposure Prophylaxis (PrEP) – Where are we now
Short Poster Presentations; "Best of Posters"
Comparison of 5 online free access expert databases to check drug-drug interactions between antiretroviral drugs and co-prescribed medications from a French cohort of HIV-infected outpatients.
Le
Polypharmacy, drug-drug interactions and potentially inappropriate prescribing in elderly patients of the swiss HIV cohort study
Marzolini
Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics of Etravirine in HIV-positive Children Ages 1-<6 Years
Ibrahim
Round Table Discussion: Two- Drug Regimens -
Moderator
Giovanni di Perri, MD, PhD
University of Turin, Italy
Panel members
Jonathan Schapiro, MD
Sheba Medical Center, Israel
Saye Khoo, MD, PhD
University of Liverpool, United Kingdom
Overview
Welcome
We are so glad that the 19th International Workshop on Clinical Pharmacology in Baltimore was a huge success. A big thank you to all of our participants and speakers, and we look forward to seeing you in at the next edition.
Committees
The members of the Organizing Committee (OC) frequently discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.
6 yearly rotating members of the Organizing Committee form the Program Committee (PC), which is responsible for day-to-day decisions.
Organizing Committee
Scientific Committee
The members of Scientific Committee assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
- Peter Anderson, MD - University of Colorado, Denver, USA
- Marta Boffito, MD - St. Stephen's Center, UK
- Stefano Bonora, MD - University of Torino, Italy
- Raffaele Bruno, MD - University of Pavia, Italy
- Dario Cattaneo, MD, PhD - University of Liverpool, UK
- Tim Cressey, BSc, MSc, PhD - Chiang Mai University, Thailand
- Rodolphe Garraffo, PharmD, PhD - Hopital Pasteur, France
- David Haas, MD - Vanderbilt University Medical Center, USA
- Saye Khoo, MD, PhD - University of Liverpool, UK
- Michael Kurowski - Therapia GmbH, Germany
- Mohammed Lamorde - Infectious Diseases Institute, Uganda
- Jacob Langness, PharmD - Abbott Northwestern Hospital in Minneapolis, USA
- Lawrence Lee, MBBS PhD - National University of Singapore, Singapore
- Helen McIlleron, MBChB, PhD - University of Cape Town, South Africa
- José Moltó, MD, PhD - Hospital Universitari Germans Trias I Pujol
- Peytavin Gilles, PharmD - Hopital Bichat, France
- Elizabeth Phillips,MD, FRCPC, FRACP - Vanderbilt University School of Medicine, USA
- Massimo Puoti, MD - Niguarda Ca'Granda Hospital
- Kellie Schoolar-Reynolds, PharmD - Food and Drug Administration, USA
- Kimberly Scarsi, PharmD, MS - University of Nebraska Medical Center
- Kimberly Struble, PharmD - Food and Drug Administration, USA
- Steve Taylor, MRCP, PhD - Birmingham Heartlands Hospital, UK
- Alice Tseng, PharmD, - Toronto General Hospital, Canada
- Stefan Zeuzem, MD - University of Frankfurt, Germany
Support
Language
Related Programs
